High SAA1 expression levels are representative for patients with poor response to sunitinib, which indicates that SAA1 could exhibit protein signatures for tyrosine kinase inhibitor therapy response prediction and might participate in sunitinib resistance of RCC patients. This evidence concerns the gene SAA1 and renal cell carcinoma.